← Research
Apr 2021 Randomized Controlled Trial
Trial of Psilocybin versus Escitalopram for Depression
Carhart-Harris R, Giribaldi B, Watts R, et al. — Centre for Psychedelic Research, Imperial College London
Published in New England Journal of Medicine
Psilocybin Depression
59 patients with moderate-to-severe depression received two 25mg psilocybin doses with placebo pills, or two 1mg psilocybin doses with daily escitalopram. The primary outcome (QIDS-SR-16 at week 6) showed no statistically significant difference between arms; most secondary outcomes favored psilocybin but weren't corrected for multiple comparisons.
Read the Full Paper at New England Journal of Medicine